Drug intelligence / Profile preview

PLGAI-002

Development stage: Unknown
Lead developer: Peptilogics
Modality: Peptides, Small Molecules

Overview

PLGAI-002 is a synthetic peptide therapeutic under early-stage development by Peptilogics for the treatment of rare genetic disorders, specifically inborn genetic diseases. The drug is classified as a new molecular entity and is currently at the discovery or research phase, with no defined mechanism of action publicly disclosed. As of March 2025, there are no clinical trial results or detailed mechanistic data available. The primary focus appears to be on congenital and inborn genetic disorders[1][2][4].

Beyond the preview

Go deeper on PLGAI-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLGAI-002.

Explore the full profile